Bausch & Lomb Corp — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 68/100
What the filing says
Parent company Bausch Health (87% owner) requested appointment of four new Bausch + Lomb directors effective Aug. 5, 2026: Thomas Appio (Bausch Health CEO), Robert Chersi, Laurence Paul MD, and Barbara Trebbi, replacing Steven Collis, Karen Ling, Thomas Ross, and Andrew von Eschenbach MD. No disagreement cited. Company reaffirmed full-year 2026 guidance: revenue $5.440–$5.540B; Adjusted EBITDA excluding Acquired IPR&D $1.025–$1.075B. Q2 2026 revenue was $1.394B (+9% reported, +8% constant currency vs. Q2 2025); operating cash flow increased to $153M from $32M Q1.
Why this rating
Material control shift—parent installs majority of board including its own CEO; represents governance change but no financial harm disclosed. Guidance reaffirmed signals operational confidence. ~12% of company market cap in annual revenue guidance, meaningful but not transformational.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.